WO2023235949A1 - Dental/medical device including polydioxanone, use of such device for guided tissue reconstruction and/or regeneration and production process of such device - Google Patents
Dental/medical device including polydioxanone, use of such device for guided tissue reconstruction and/or regeneration and production process of such device Download PDFInfo
- Publication number
- WO2023235949A1 WO2023235949A1 PCT/BR2023/050185 BR2023050185W WO2023235949A1 WO 2023235949 A1 WO2023235949 A1 WO 2023235949A1 BR 2023050185 W BR2023050185 W BR 2023050185W WO 2023235949 A1 WO2023235949 A1 WO 2023235949A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- present
- bone
- regeneration
- membrane
- defects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0003—Not used, see subgroups
- A61C8/0004—Consolidating natural teeth
- A61C8/0006—Periodontal tissue or bone regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
- C01B32/182—Graphene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
- A61F2/105—Skin implants, e.g. artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
- A61F2/142—Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Definitions
- the present invention relates to a dental/medical device consisting of an absorbable synthetic membrane, preferably white to gray in color, based on poly(dioxanone) (PDO or PDS) and optionally graphene and stem cells, to be used in the tissue reconstruction and/or regeneration of bone defects and other connective tissues such as gingiva, skin, cartilage and cornea, for example, for application in the medical-dental area.
- PDO or PDS poly(dioxanone)
- stem cells optionally graphene and stem cells
- the present invention relates to the use of said device for the above-related applications and to the process of preparing said device.
- GTR guided tissue regeneration
- Each patient had a pair of contralaterally located deep intraosseous defects, interproximal periodontal defects with a probing pocket depth (PPD) of at least 6 mm, and radiographic evidence of angular bone loss of at least 4 mm at baseline.
- PPD probing pocket depth
- CAL clinical attachment level
- V-rAG relative vertical attachment gain
- quantitative digital radiographic subtraction amount and area of bone density changes
- Postoperative membrane exposures occurred at 14 PDS treated sites and 2 PLA treated sites.
- both membranes provided a significant gain in CAL [median values: 6 months (PDS vs. PLA: 3.0 vs.
- PH plaque index
- Gl gingival index
- PPD probing pocket depth
- PAL-V vertical probing insertion levels
- the document KR 101636778 discloses a method for producing a biodegradable nanofiber sheet for tissue regeneration. It makes use of graphene oxide, given its properties, particularly hydrophilicity and flexibility, which play an important role in cell proliferation and differentiation. It uses the electrospinning technique to generate graphene oxide fibers and synthetic and natural polymers, as a support for tissue regeneration. Among these polymers is polydioxanone.
- Document CN 105126167 describes bone tissue repair and reconstruction, and particularly to a method of preparation and support for a 3D printed, porous titanium-based alloy surface functionalized biological coating for bone tissue repair and reconstruction.
- the functionalized porous frame made of 3D printed metal features a functionalized bioactive nanocomposite coating on the surface of fibroin oxide- graphene silk. It also employs polymers such as polydioxanone.
- dura mater reconstruction periosteum replacement
- spine yellow ligament replacement
- Figure 1 illustrates the structure of the present invention
- Figure 2 illustrates the structure of the present invention in a preferred embodiment (comprises graphene);
- Figure 3 illustrates the structure of the present invention in a preferred embodiment in which (A) the present invention comprising 0.52% reduced graphene oxide, (B) the present invention comprising 0.71 % reduced graphene oxide and (C) the present invention comprising 1.35% reduced graphene oxide;
- Figure 4 is a graph that shows the relationship between the extensional stress and the deformation of the present invention in the configurations illustrated in Figure 3;
- Figure 5 illustrates chondrocytes integration - chondrogenic differentiation on the present invention at incubation days 5 (a and b) and 1 1 (c and d).
- the present invention achieves these and other objectives by means of a dental/medical device particularly indicated for guided tissue reconstruction and/or regeneration of bone defects and other connective tissues consisting of an absorbable synthetic membrane comprising poly(dioxanone) with a substantially rectangular cross section with thickness varying between 0.05 mm and 2.00 mm, width varying between 15 mm and 200 mm and length varying between 20 mm and 200 mm.
- the present invention achieves these and other objectives by the use of the above device to be for guided tissue reconstruction and/or regeneration of bone defects and other connective tissues such as gingiva, skin, cartilage and cornea, for example.
- the present invention achieves these and other objectives by means of a process for preparing the device of the present invention which comprises the following steps: a. raw material is placed in a vacuum stove at room temperature; b. the raw material is weighed to prepare the dissolution with organic solvents; c. employee performs the machine setup by inserting the appropriate program for the operation; d. after loading the machine with the polymeric dissolution, the machine is activated, and the production of the membrane takes place with a predetermined flow rate; e. the membrane blanket is removed and placed in a vacuum stove for residual organic solvent removal; f. the blanket is sent to the CO2 laser cutter for the membrane cutting process; g. membranes are stored in an airtight container; h. the membranes are individually packed.
- the present invention in a first preferred embodiment, relates to a dental and/or medical device comprising a polydioxanone membrane. Furthermore, said membrane has sub and micrometric fibers whose physicochemical and morphological characteristics facilitate the diffusion of biological fluids and cell adhesion. [00033]
- the device of the present invention is indicated to be used in the reconstruction and/or guided tissue regeneration of bone defects and other connective tissues such as gingiva, skin, cartilage or cornea, for example.
- the device of the present invention comprises a membrane prepared from poly(dioxanone) as it is a resorbable alloplastic material. This type of material is indicated for bone repair because it is concomitantly replaced by neoformed tissue. In this way, the device of the present invention can be used both as a mechanical barrier to maintain the defect space, and as a mesh for the volume increase/reconstruction of bone tissue and soft tissues.
- the physical structure and composition of the membrane allows for controlled resorption within an estimated period of 3 to 12 months.
- said membrane is synthetic resorbable poly(dioxanone) and has a microstructure in the form of a mesh that works as a mechanical barrier promoting space maintenance and an efficient tissue repair or regeneration process.
- the device of the present invention is for single use, supplied in a sterile condition and available in various designs and dimensions.
- the device of the present invention is presented in the following dimensions: thickness ranging from 0.05 mm to 2.00 mm, width ranging from 15 mm to 200 mm and length ranging from 20 mm to 200 mm.
- the present invention is formed by filaments with diameters between 500 nanometers to 2 micrometers.
- the present invention comprises a technical differential since it is produced by electrospinning which confers higher resistance in relation to the PDS plate process which is molding/injection as shown in the table below:
- the present invention comprises graphene or other compounds made from carbon such as nanocarbon and carbon tubes.
- the presence of these components adds mechanical strength to the device of the present invention and confers antibacterial property.
- the present invention comprises stem cells preferably being autogenous adult mesenchymal stem cells obtained from dermal punch of the patient.
- the present invention comprises graphene and stem cells.
- This embodiment is illustrated in Figure 5: on human adipose-derived stem cells (hASCs) chondrogenic differentiation fiber coating and morphological change were noted after 1 1 days of differentiation, on both evaluated membranes, with a great structural organization on the present invention.
- hASCs human adipose-derived stem cells
- Embodiments of the present invention that comprise stem cells have the following characteristics:
- the device of the present invention not only for cartilage regeneration, but also for the regeneration of other tissues, such as bone tissue.
- the techniques of use and application of the device of the present invention may vary according to the preference of the surgeon (doctor or dentist), being up to him to choose the therapeutic approach, model and dimensions of the product, application technique, the use of a fixation or use of complementary biomaterials, as well as the criteria for monitoring and evaluating the results of the surgery.
- Proper site preparation involves treating the entire area that will be covered by the device.
- the cavity and/or bone tissue or soft tissue and the grafted area must have a homogeneous surface and the final shape of the desired recipient bed already prepared, as well as controlled bleeding, so that the device has a perfect adaptation to the recipient bed and achieve the expected results.
- the surgeon In the manipulation and implantation procedure of the device of the present invention, the surgeon should use only appropriate and sterile surgical instruments. And, before the surgical procedure, the surgeon (doctor or dentist) must carry out a rigorous preoperative planning, through clinical and imaging exams (radiographs or computed tomography). It should also consider the need for a detailed anamnesis and complementary tests on the patient's general health (complete blood count, coagulogram, calcium dosage, etc.), since this information directly influences the biological response of the organism to the installation of the device of the present invention and then define a surgical plan in advance, with the selection of the model and size of the device best suited to the condition of your patient.
- the surgical protocol must be performed according to the surgeon's references and previous experiences, always considering the most appropriate choice of the model and size of the device, the technique, the installation sequence and the use of fixation methods (sutures, tacks or screws), always based on in conventional and established therapeutic techniques of guided tissue regeneration and bone grafting.
- the device of the present invention guarantees a high swelling efficiency
- the device of the present invention acts as a mechanical barrier promoting space maintenance and efficient guided tissue regeneration
- the device of the present invention has a morphology and surface topography similar to the extracellular matrix, whose physicochemical and morphological characteristics facilitate the diffusion of biological fluids and cell adhesion;
- the device of the present invention is designed and manufactured ensuring safety and efficacy in relation to systemic toxicity
- the device of the present invention is safe and effective in terms of biological compatibility. Physicochemical analyzes and pre-clinical tests ensure its characteristics, performance and functionality;
- the device of the present invention was designed and manufactured in order to eliminate the risks linked to temperature conditions, ensuring the integrity of the product while it is in its validity period;
- the present invention is a guided tissue regeneration device indicated to intraosseous defects due to congenital, post-traumatic, post-surgical problems, or as a result of diseases, such as periodontal and peri-implant lesions; the present invention promotes alveolar ridge augmentation/reconstruction associated with bone grafts or synthetic bone substitutes for guided tissue regeneration;
- the present invention acts as a barrier favoring the maintenance of the space of the bone cavity or the space created for the increase of alveolar rim.
- the dental/medical device particularly indicated for guided tissue reconstruction and/or regeneration of bone defects and other connective tissues including gums, skin, cartilage or cornea comprises graphene (reduced graphene oxide).
- the structural difference of this preferred embodiment can be observed from Figure 1 compared to Figure 2.
- the said device comprises graphene, preferably reduced graphene oxide in a concentration ranging between 0.52% and 1 .35%.
- control membrane presents the highest value of extensional stress and the lowest deformation, favoring rupture.
- the SEM images show a morphological structure with a random weave of fibers in submicron order.
- the laser cutting proved to be effective in the images obtained by SEM, whose images revealed that the difference in the morphology of the membrane in the region distant and close to the laser cutting site is restricted to a width of the order of 30 pm.
- DSC Differential Scanning Calorimetry
- the Maximized Dermal Sensitization assay consists of analyzing the material's ability to cause an immunologically mediated skin reaction to a substance, characterized by the appearance of edema and/or erythema.
- the maximized method uses an adjuvant capable of stimulating the immune response in order to enhance the sensitivity of the method (Freund's Complete Adjuvant - FCA).
- the device of the present invention had to undergo an extraction process to be inoculated (see ISO 10993-12: Sample preparation and reference materials, 2012). For this, the device was extracted at 37 S C for 72 hours in a Shaker incubator at 100 rpm in a proportion of 6 cm 2 of the membrane, for 1 mL of 0.9% sodium chloride solution.
- Intracutaneous Reactivity test consists of the evaluation of local adverse effects occurring after the inoculation of a substance intracutaneously in a single dose. As it is a solid material, the device of the present invention had to undergo an extraction process to be inoculated (see ISO 10993-12: Sample preparation and reference materials, 2012). The test was performed on rabbits (Oryctolagus cuniculus - New Zealand), randomly selected and shaved in the dorsum region, in an area of approximately 10 x 15 cm, approximately 24 hours before the application of the test substance.
- the back of the animals was divided into a test area and a control area with the aid of a hydrographic pen and the device extract was applied to 5 sites in the test area, in a volume of 0.2 mL per site, intracutaneously, totaling 1 ml of test substance per animal.
- the extraction vehicle sodium chloride 0.9%) was applied in the control area under the same conditions of application of the device.
- Application sites were evaluated 24, 48 and 72 hours after application and were classified as to the absence or presence of edema and erythema. The result showed that none of the animals presented edema or erythema neither for the sites (Test) nor for the control sites (sodium chloride 0.9%).
- the test substance was found to be satisfactory.
- Acute systemic toxicity is the assessment of possible health risk and adverse effects caused by a single exposure to a substance. These studies provide information on systemic toxic effects and serve as a basis for estimating the safety of the substance. The tests carried out by were based on the ISO 10993-1 1 : Biological evaluation of medical devices - part 1 1 : Tests for systemic toxicity (2006) and its 2017 update. As it is a solid material, the test substance had to undergo an extraction process in 0.9% sodium chloride solution to be inoculated, according to ISO 10993-12: Sample preparation and reference materials, 2012.
- test substance extract was applied intravenously in a volume of 50 mL/kg of animal weight; and the extraction vehicle was applied to the control group, under the same conditions as the test substance in 10 mice (Mus musculus - Swiss). After application, the animals were regularly observed at 1 , 24, 48 and 72 hours after application, for the presence of toxic signs, such as changes in the skin, eyes, respiratory, cardiovascular and gastrointestinal systems, changes in motor activity, salivation, seizures, hairy erection, weight loss and death. The test substance was evaluated according to pharmacopoeia criteria, which determine that if all animals survive and do not show clinical signs of toxicity, the test substance will be considered in compliance with the adopted requirements.
- the tests performed were based on the ISO 10993-6: Biological evaluation of medical devices - part 6: Tests for local effects after implantation (2007) and in the ISO 10993-1 1 : Biological evaluation of medical devices - part 1 1 : Tests for systemic toxicity (2006) and update (2016).
- the subchronic systemic toxicity test assesses the existence of possible health risks and/or possible adverse effects caused by repeated and/or continuous exposure to a substance.
- the implantation assay evaluates its local effects after direct contact of the test substance with the tissues to which it is exposed. Together these assays provide information on possible systemic and target organ toxic effects, characterize the history and evolution of tissue response and serve as a basis for estimating the biological safety of the test substance.
- the present trial aimed to evaluate the local and systemic effects of the device product of the present invention applied on bone tissue (according to the indication and purpose for which the product is intended) for 90 days.
- the tests were carried out in rabbits (Oryctolagus cuniculus - New Zealand), which underwent insertion of the device in the tibia, under a specific protocol. After the procedure, the animals were weighed and evaluated for clinical signs of toxicity that included, but were not limited to, convulsion, mutilation, prostration, ataxia, tremors, local inflammation, dyspnea, tearing, salivation, diarrhea, piloerection, and cachexia, at baseline and weekly throughout the study period.
- the bone implant test evaluates the local effects after the implantation of a material in an animal species, with the objective of characterizing the history and evolution of the tissue response after the implantation of a medical device, also evaluating its biological safety.
- Both the device of the present invention (test) and the reference product (control) were inserted over rounded incisions of 3 mm in diameter in the region close to the tuberosity of the tibia of Rabbits - Oryctolagus cuniculus - New Zealand.
- the present study aimed to analyze the safety and efficacy of cartilaginous repair capacity and action on the joint inflammatory response in sheep of the present invention Test Item.
- the methodology consisted of the evaluation of implantation sites after the treatment of chondral lesion in adult female sheep (Ovis aries), by means of anatomopathological analyses when compared to the control or reference treatments.
- the chondral lesion of 10 mm in diameter was induced in the support center of the medial condyle of the direct and left femur, until the exposure of the subchondral bone of 16 sheep without signs of osteoarticular or systemic alterations.
- each animal received an implantation site in the lesion of the left pelvic limb and a control treatment (in the lesion of the right pelvic limb (n of 8 per treatment).
- the control treatments consisted of infiltration of 0.9% NaCI saline solution (Control), or five microfractures in the subchondral bone, followed by infiltration of 0.9% NaCI saline solution (Microfracture).
- test and reference item consisted of fixation of the membranes of the present invention (Test item) and ChondroGide® (Reference item) on the microfracture, using fibrin glue.
- the animals were exposed to the treatment for 26 weeks. At the end of the period, all animals were anesthetized, euthanized and macroscopically examined. Tissue samples, implant site specimens were processed and sent for imaging and macroscopic analyses.
- Computed tomography images were obtained from the distal segment of the femur, after dissection and removal of adjacent soft tissues through the SHIMADZU equipment, Model: SCT - 7800 CT, with 0.5 mm slices, standardized in mA 100 and KVP 120.
- Computed tomography images were obtained from the 32 knees included in the study. For evaluation, the images were visualized by the Synapse PD-S Viewer software (Fujifilm - Tokyo, Japan), in a transverse plane. The determination of subchondral sclerosis was performed by bone densitometry analysis using the Imaged software.
- the present invention presented superiority in relation to the control and microfracture treatments, and equality in relation to the treatment with the reference item. [00083] Further, no adverse reactions were observable at the sheep joint using the present invention.
- the present invention and collagen scaffold presented superior ICRS scores compared to the control group (P ⁇ 0,0001 and P ⁇ 0,01 , respectively). Cartilage repair in the present invention group was better than in the microfracture-only group (P ⁇ 0.01 ), suggesting that the present invention provides better cell support and promotes chondrogenic differentiation of local mesenchymal cells. In addition, there were no statistical differences between groups in sheep synovial fluid biomarkers.
- the present invention is a safe scaffold that provides better cell support and shows potential improvement in chondrogenic differentiation, which may improve the quality of cartilage repair.
- said invention s mechanical and physicochemical properties allow personalization and fixation by suture on the host of them.
- microfracturing technique in sheep promotes cyst formation, while the present invention has a protective effect and can reduce SCB cyst formation and sclerosis.
- the process for preparing the device of the present invention comprises the following steps: a. raw material is placed in a vacuum stove at room temperature; b. the raw material is weighed to prepare the dissolution with organic solvents; c. employee performs the machine setup by inserting the appropriate program for the operation; d. after loading the machine with the polymeric dissolution, the machine is activated, and the production of the membrane takes place with a predetermined flow rate; e. the membrane blanket is removed and placed in a vacuum stove for residual organic solvent removal; f. the blanket is sent to the CO2 laser cutter for the membrane cutting process; g. membranes are stored in an airtight container; h.
- the membranes are individually packaged under laminar flow in primary packaging in the form of a polyethylene terephthalate (PET) blister; then the blister is heat-sealed with Tyvek type surgical grade paper; 01 (one) blister of the product is placed in a secondary packaging in the form of a PET/aluminum sachet under laminar flow and the products are placed in an envelope for sterilization in surgical grade paper, whose envelope is thermo-sealed and receives a label indicating sterilization by EtO. This process is carried out to allow the EtO gas to penetrate effectively inside the package, sterilizing the product.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dentistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Composite Materials (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020247043064A KR20250020505A (ko) | 2022-06-06 | 2023-06-06 | 폴리디옥사논을 포함하는 치과/의료 기기, 유도 조직 재건 및/또는 재생을 위한 이 기기의 용도 및 이 기기의 제조 공정 |
| JP2024570905A JP2025519387A (ja) | 2022-06-06 | 2023-06-06 | ポリジオキサノンを含む歯科/医療用デバイス、組織再建誘導及び/又は再生のための当該デバイスの使用、並びに当該デバイスの製造方法 |
| AU2023282946A AU2023282946A1 (en) | 2022-06-06 | 2023-06-06 | Dental/medical device including polydioxanone, use of such device for guided tissue reconstruction and/or regeneration and production process of such device |
| EP23818658.9A EP4536305A4 (en) | 2022-06-06 | 2023-06-06 | DENTAL/MEDICAL DEVICE COMPRISING POLYDIOXANONE, USE OF SUCH A DEVICE FOR GUIDED TISSUE RECONSTRUCTION AND/OR REGENERATION, AND METHOD FOR PRODUCING SUCH A DEVICE |
| GB2417460.9A GB2635971A (en) | 2022-06-06 | 2023-06-06 | Dental/medical device including polydioxanone, use of such device for guided tissue reconstruction and/or regeneration and production process of such device |
| CA3257464A CA3257464A1 (en) | 2022-06-06 | 2023-06-06 | DENTAL/MEDICAL DEVICE COMPRISING POLYDIOXANONE, USE OF SUCH A DEVICE FOR GUIDED TISSUE RECONSTRUCTION AND/OR REGENERATION, AND METHOD FOR PRODUCING SUCH A DEVICE |
| US18/872,425 US20260000490A1 (en) | 2022-06-06 | 2023-06-06 | Dental/medical device including polydioxanone, use of such device for guided tissue reconstruction and/or regeneration and production process of such device |
| CN202380044214.6A CN119300872A (zh) | 2022-06-06 | 2023-06-06 | 包括聚二氧杂环己酮的牙科/医疗器械、该器械用于引导组织重建和/或再生的用途及该器械的生产方法 |
| MX2024014917A MX2024014917A (es) | 2022-06-06 | 2024-11-29 | Producto medico o odontologico, incluido el polidioxanona, uso de dicho producto para la reconstruccion guiada de tejidos y/o la regeneracion y el proceso de produccion de dicho producto |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263349344P | 2022-06-06 | 2022-06-06 | |
| US63/349,344 | 2022-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023235949A1 true WO2023235949A1 (en) | 2023-12-14 |
Family
ID=89117262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR2023/050185 Ceased WO2023235949A1 (en) | 2022-06-06 | 2023-06-06 | Dental/medical device including polydioxanone, use of such device for guided tissue reconstruction and/or regeneration and production process of such device |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260000490A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4536305A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025519387A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250020505A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119300872A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023282946A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3257464A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2635971A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024014917A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023235949A1 (cg-RX-API-DMAC7.html) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170021060A1 (en) * | 2015-07-24 | 2017-01-26 | The Texas A&M University System | Shape memory polymer scaffolds for tissue defects |
| US20180326123A1 (en) * | 2017-05-10 | 2018-11-15 | Board Of Trustees Of The University Of Arkansas | Biocompatible structure for tissue regeneration and methods of making and using same |
| US20200155724A1 (en) * | 2013-10-04 | 2020-05-21 | Oxford University Innovation Limited | Scaffold |
| US20210244854A1 (en) * | 2020-02-06 | 2021-08-12 | Board Of Trustees Of The University Of Arkansas | Expandable bone and tissue regeneration system, and applications of same |
| WO2022081697A1 (en) * | 2020-10-14 | 2022-04-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hybrid micro molding-fiber deposition substrate processing for cell biology manipulation and local anisotropy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200330641A1 (en) * | 2019-04-17 | 2020-10-22 | Shulan Jiang | Biodegradable graphene oxide biocomposite fibrous membrane, preparation method and uses thereof |
-
2023
- 2023-06-06 WO PCT/BR2023/050185 patent/WO2023235949A1/en not_active Ceased
- 2023-06-06 CA CA3257464A patent/CA3257464A1/en active Pending
- 2023-06-06 EP EP23818658.9A patent/EP4536305A4/en active Pending
- 2023-06-06 US US18/872,425 patent/US20260000490A1/en active Pending
- 2023-06-06 AU AU2023282946A patent/AU2023282946A1/en active Pending
- 2023-06-06 GB GB2417460.9A patent/GB2635971A/en active Pending
- 2023-06-06 JP JP2024570905A patent/JP2025519387A/ja active Pending
- 2023-06-06 KR KR1020247043064A patent/KR20250020505A/ko active Pending
- 2023-06-06 CN CN202380044214.6A patent/CN119300872A/zh active Pending
-
2024
- 2024-11-29 MX MX2024014917A patent/MX2024014917A/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200155724A1 (en) * | 2013-10-04 | 2020-05-21 | Oxford University Innovation Limited | Scaffold |
| US20170021060A1 (en) * | 2015-07-24 | 2017-01-26 | The Texas A&M University System | Shape memory polymer scaffolds for tissue defects |
| US20180326123A1 (en) * | 2017-05-10 | 2018-11-15 | Board Of Trustees Of The University Of Arkansas | Biocompatible structure for tissue regeneration and methods of making and using same |
| US20210244854A1 (en) * | 2020-02-06 | 2021-08-12 | Board Of Trustees Of The University Of Arkansas | Expandable bone and tissue regeneration system, and applications of same |
| WO2022081697A1 (en) * | 2020-10-14 | 2022-04-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hybrid micro molding-fiber deposition substrate processing for cell biology manipulation and local anisotropy |
Non-Patent Citations (7)
| Title |
|---|
| BRESSAN, E. ET AL.: "Graphene based scaffolds effects on stem cells commitment", J TRANSL MED, vol. 12, 2014, pages 296, XP021202916, Retrieved from the Internet <URL:https://doi.org/10.1186/s12967-014-0296-9> DOI: 10.1186/s12967-014-0296-9 * |
| SASKA, S. ET AL.: "Polydioxanone-Based Membranes for Bone Regeneration", POLYMERS, vol. 13, 2021, pages 1685, XP093116313, Retrieved from the Internet <URL:https://doi.org/10.3390/polym13111685> DOI: 10.3390/polym13111685 * |
| SCAFFARO ROBERTO, MAIO ANDREA, LOPRESTI FRANCESCO, BOTTA LUIGI: "Nanocarbons in Electrospun Polymeric Nanomats for Tissue Engineering: A Review", POLYMERS, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (M DP I) AG., CH, vol. 9, no. 12, CH , pages 76, XP093116544, ISSN: 2073-4360, DOI: 10.3390/polym9020076 * |
| See also references of EP4536305A4 * |
| SHAH, S. ET AL.: "Guiding Stem Cell Differentiation into Oligodendrocytes Using Graphene-Nanofiber Hybrid Scaffolds", ADV. MATER., vol. 26, 2014, pages 3673 - 3680, XP055614054, Retrieved from the Internet <URL:https://doi.org/10.1002/adma.201400523> DOI: 10.1002/adma.201400523 * |
| XU YIBO, CHEN CHUANXIN, HELLWARTH PETER B., BAO XIAOPING: "Biomaterials for stem cell engineering and biomanufacturing", BIOACTIVE MATERIALS, vol. 4, 1 December 2019 (2019-12-01), pages 366 - 379, XP093116545, ISSN: 2452-199X, DOI: 10.1016/j.bioactmat.2019.11.002 * |
| YU LUO ET AL.: "Enhanced Proliferation and Osteogenic Differentiation of Mesenchymal Stem Cells on Graphene Oxide-Incorporated Electrospun Poly(lactic-co-glycolic acid", NANOFIBROUS MATS ACS APPLIED MATERIALS & INTERFACES, vol. 7, no. 11, 2015, pages 6331 - 6339, XP055579579, DOI: 10.1021/acsami.5b00862 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4536305A1 (en) | 2025-04-16 |
| AU2023282946A1 (en) | 2024-12-19 |
| MX2024014917A (es) | 2025-01-09 |
| GB2635971A (en) | 2025-06-04 |
| CN119300872A (zh) | 2025-01-10 |
| KR20250020505A (ko) | 2025-02-11 |
| US20260000490A1 (en) | 2026-01-01 |
| CA3257464A1 (en) | 2023-12-14 |
| JP2025519387A (ja) | 2025-06-26 |
| EP4536305A4 (en) | 2026-06-17 |
| GB202417460D0 (en) | 2025-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Byun et al. | Biodegradable magnesium alloy (WE43) in bone‐fixation plate and screw | |
| US11786634B2 (en) | Demineralized bone matrix having improved handling characteristics | |
| JP2021184903A (ja) | 骨間隙を充填するための材料および方法 | |
| Pobloth et al. | Tubular open‐porous β‐tricalcium phosphate polycaprolactone scaffolds as guiding structure for segmental bone defect regeneration in a novel sheep model | |
| Van Leeuwen et al. | Poly (trimethylene carbonate) and biphasic calcium phosphate composites for orbital floor reconstruction: a feasibility study in sheep | |
| Malaiappan et al. | Osteogenic potential of magnesium oxide nanoparticles in bone regeneration: A systematic review | |
| Heinz et al. | Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects: a randomized controlled clinical study | |
| Watanabe et al. | Resorbable bilayer membrane made of L-lactide-ε-caprolactone in guided bone regeneration: an in vivo experimental study | |
| Marano et al. | Is there an ideal implant for orbital reconstructions? Prospective 64-case study | |
| US20260000490A1 (en) | Dental/medical device including polydioxanone, use of such device for guided tissue reconstruction and/or regeneration and production process of such device | |
| He et al. | Electrospun polycaprolactone incorporated with fluorapatite nanoparticles composite scaffolds enhance healing of experimental calvarial defect on rats | |
| WO2024197316A1 (en) | Bone growth composition | |
| US20220233751A1 (en) | Bone putty for bone pore and void filling | |
| Liljensten et al. | Hydroxyapatite granule/carrier composites promote new bone formation in cortical defects | |
| EP2771039B1 (en) | Artificial bone implants, or bone grafts, of polymeric composites with bone forming properties | |
| Mahmood et al. | In Vivo evaluation of the novel nanocomposite porous 3d scaffold in a rabbit model | |
| Pyhältö et al. | Fixation of distal femoral osteotomies with self-reinforced poly (L/DL) lactide 70: 30 and self-reinforced poly (L/DL) lactide 70: 30/bioactive glass composite rods. An experimental study on rabbits | |
| Hafez et al. | Evaluation of chitosan/hydroxyapatite scaffold on the healing of osseous defects in jaw bones (clinical study) | |
| Haghighi et al. | Therapeutic potential of nanofibrous scaffolds in calvarial bone regeneration | |
| ElSafty et al. | The effect of bone marrow aspirate concentrate in the treatment of mandibular cystic defects. A randomized clinical trial | |
| Humadi et al. | The Impact of Two Platelet Concentrates on Healing of Surgically Created Bone Defects in Sheep (Radiological Analysis) | |
| Wang et al. | PGA-TMC/PTMC/nHA composite membrane with synergistic barrier and osteogenic functions for enhanced bone defect regeneration | |
| Kovaleva et al. | Biotechnology in medical application of biocomposite materials for optimization of bone tissue regeneration | |
| JP2025130730A (ja) | 多孔質骨誘導性複合体 | |
| Porta | Design and optimization of 3D Bioplotted scaffolds with a multi-layered architecture for osteochondral tissue regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23818658 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| ENP | Entry into the national phase |
Ref document number: 202417460 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20230606 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2417460.9 Country of ref document: GB |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2024/014917 Country of ref document: MX Ref document number: AU2023282946 Country of ref document: AU Ref document number: 202380044214.6 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024570905 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024/017964 Country of ref document: TR |
|
| ENP | Entry into the national phase |
Ref document number: 2023282946 Country of ref document: AU Date of ref document: 20230606 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 20247043064 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202547000064 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023818658 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2025100016 Country of ref document: RU |
|
| WWP | Wipo information: published in national office |
Ref document number: 202380044214.6 Country of ref document: CN |
|
| ENP | Entry into the national phase |
Ref document number: 2023818658 Country of ref document: EP Effective date: 20250107 |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024025130 Country of ref document: BR |
|
| WWP | Wipo information: published in national office |
Ref document number: 2025100016 Country of ref document: RU Ref document number: 1020247043064 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 2024/017964 Country of ref document: TR |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112024025130 Country of ref document: BR Free format text: 1) APRESENTE NOVA FOLHA DO RESUMO OU DA PAGINA 1 DO RELATORIO DESCRITIVO ADAPTADA AO ART. 24 INCISO IV DA PORTARIA NO 14/2024, UMA VEZ QUE O TITULO DO RESUMO APRESENTADO E DIVERGENTE DO TITULO DO RELATORIO DESCRITIVO ENVIADOS NA PETICAO NO 870240102363 DE 02/12/2024. 2) APRESENTE NOVAS FOLHAS DO RELATORIO DESCRITIVO ADAPTADAS AOS ARTS. 20 DA PORTARIA NO 14/2024, UMA VEZ QUE O CONTEUDO ENVIADO NA PETICAO NO 870240102363 ENCONTRA-SE FORA DA NORMA POIS AS TABELAS NAO FORAM NUMERADAS. 3) APRESENTE A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE US 63/349,344 DE 06/06/2022 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTA CONFORME O PARAGRAF |
|
| WWP | Wipo information: published in national office |
Ref document number: 2023818658 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 112024025130 Country of ref document: BR Kind code of ref document: A2 Effective date: 20241202 |
|
| WWP | Wipo information: published in national office |
Ref document number: 2417460.9 Country of ref document: GB |